Postpartum cells derived from placental tissue, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-2017239299-A1
Application number	US-201715443602-A
Country	US
Kind code	A1
Filing date	Feb 27, 2017
Priority date	Jun 27, 2003
Publication date	Aug 24, 2017
Grant date	—

Abstract

Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

First claim

What is claimed:

1 . An extracellular matrix produced by an isolated human placenta-derived cell derived from human postpartum placenta tissue substantially free of blood, wherein the placenta-derived cell self-renews and expands in culture, is multipotent, requires L-valine for growth, grows in about 5% to about 20% oxygen, and further comprises the following characteristics:
a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C; b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP,DQ, as detected by flow cytometry; and c) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 and renin.

2 . A matrix comprising the extracellular matrix of claim 1 .

3 . The matrix of claim 2 , wherein said matrix is a three-dimensional scaffold.

4 . The matrix of claim 3 comprising VICRYL nonwoven scaffold, 35/65 PCL/PGA foam, an in situ polymerizable gel, or a self-assembling peptide hydrogel.

5 . The extracellular matrix of claim 1 , wherein the isolated human placenta-derived cell is cryopreserved.

6 . The extracellular matrix of claim 1 , wherein the placenta-derived cell further comprises the following characteristics:
d) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry e) secretes of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), interleukin 8 (IL8), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and f) lack of secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1 beta (MIP1b), 1309, and macrophage-derived chemokine (MDfC), as detected by ELISA.

7 . The extracellular matrix of claim 1 , wherein the placenta-derived cell is of a neonatal origin.

8 . The extracellular matrix of claim 1 , wherein said placenta-derived cell is of a maternal origin.

9 . The extracellular matrix of claim 1 , wherein the placenta-derived cell has the ability to differentiate into a mesodermal, ectodermal, or endodermal phenotype.

10 . The extracellular matrix of claim 1 , wherein the placenta-derived cell can undergo at least 40 population doublings in culture.

11 . The extracellular matrix claim 1 , further comprising genetically engineering the placenta-derived cell to produce a protein of interest.

12 . The extracellular matrix of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6074.

13 . The extracellular matrix of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6075.

14 . The extracellular matrix of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6079.

15 . The extracellular matrix of claim 1 , wherein the placenta-derived cell produces granulocyte chemotactic protein-2 (GCP-2).

Assignees

• Depuy Synthes Products Inc

Inventors

• Kihm Anthony J
• Harris Ian Ross
• Mistry Sanjay
• Harmon Alexander M
• Messina Darin J
• Seyda Agnieszka
• Yi Chin-Feng
• Gosiewska Anna

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title